Company intelligence / Profile preview

NantKwest, Inc.

San Diego, California, USAimmunitybio.com ↗

Ownership: Private
Employees: ~100
Development stage: Phase 3

Overview

NantKwest’s off-the-shelf natural killer cell therapies demonstrated safety and early efficacy signals in multiple phase I/II clinical trials for both hematologic cancers and solid tumors. Combination approaches with immunomodulators showed durable responses in some late-stage metastatic cancers.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Cell therapy (natural killer cells)Engineered cell therapies (CAR-NK, haNK, t-haNK)
Industry: Biotech

Drug pipeline

1 asset

Anktiva

Phase 3

Indications: Bladder cancer, Non-muscle invasive bladder cancer

Partnerships

ImmunityBioVarious pharmaceutical companies licensed non-clinical use of CD16-bearing aNK lines for antibody testingAdditional collaborations via the NantWorks ecosystem

Beyond the preview

Go deeper on NantKwest, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NantKwest, Inc..

Explore the full profile